title: Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficiency and safety of simultaneous islet and kidney transplantation in patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
  
  
  METHODS
  Seven patients with type 1 diabetes and end-stage renal failure were transplanted with allogenic islets and kidneys procured from brain-dead donors. To prevent organ rejection, patients received alemtuzumab for induction immunosuppression, followed by sirolimus and tacrolimus. No glucocorticoids were given at any time.
  
  
  RESULTS
  The median duration of follow-up was 18.3 months (range 13-31). Kidney survival was 100%. Four patients became insulin independent at 1 year. The other three reduced insulin use to less than 25% of the amount required before transplantation. Serum C-peptide levels were significantly greater posttransplant in all patients, indicating continued islet function. No major procedure-related complications were observed.
  
  
  CONCLUSIONS
  Our results demonstrate that a steroid-free immunosuppressive regimen consisting of alemtuzumab, sirolimus, and tacrolimus is feasible for simultaneous islet and kidney transplantation. The question of whether this induction regimen is superior to more standard induction deserves large studies.
authors.affiliation: Organ Transplant Institute, Fuzhou General Hospital, Fuzhou, China. doctortjm@yahoo.com
authors.forename: Jianming
authors.initials: J
authors.lastname: Tan
authors.forename: Shunliang
authors.initials: S
authors.lastname: Yang
authors.forename: Jinquan
authors.initials: J
authors.lastname: Cai
authors.forename: Junqi
authors.initials: J
authors.lastname: Guo
authors.forename: Lianghu
authors.initials: L
authors.lastname: Huang
authors.forename: Zhixian
authors.initials: Z
authors.lastname: Wu
authors.forename: Jin
authors.initials: J
authors.lastname: Chen
authors.forename: Lianming
authors.initials: L
authors.lastname: Liao
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects / Q000379:methods*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D020123:Sirolimus; D016559:Tacrolimus